DaVita Posts $3.58B in Revenue for Third Quarter 2026
DaVita Inc. reported consolidated revenues of $3.578 billion for Q3 2026, the company announced from its Denver headquarters.
DaVita Inc. (NYSE: DVA) disclosed its financial and operating results for the third quarter ending September 30, 2026, reporting consolidated revenues of $3.578 billion, the kidney care company announced Wednesday from Denver.
The quarterly filing marks another reporting period for one of the largest providers of dialysis services in the United States, a sector closely watched by healthcare investors for signals on patient volume trends, reimbursement rates, and operational efficiency.
Read more Biohaven FDA Resubmission Accepted for Ataxia Drug Troriluzole →
While the revenue figure was disclosed, full details on operating income and additional line items were included in the company's broader earnings release. Investors and analysts typically scrutinize DaVita's per-treatment metrics and center count alongside top-line revenue when assessing the company's performance against prior periods and Wall Street expectations.
DaVita operates hundreds of outpatient dialysis centers nationwide, serving patients with chronic kidney disease and end-stage renal disease. The company's quarterly results are regarded as a bellwether for the broader dialysis and kidney care industry, which faces ongoing pressures from labor costs, government reimbursement policy, and an evolving landscape of home dialysis adoption.
Continue reading at Earnings for the full breakdown of DaVita's Q3 2026 operating income, per-share results, and management commentary.
